Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16656855 | 0.88 | TSHR (0.53) | POLBHPGDTSHR | |
| SCHEMBL21267332 | 0.87 | MAPT (0.54) | CPS1HPGDMTORKMT2ACNR1 | |
| SCHEMBL11919305 | 0.87 | TSHR (0.56) | POLBHPGDRAB9ANPC1KMT2A | |
| SCHEMBL21267340 | 0.86 | CPS1 (0.49) | CPS1POLBHPGDMTORKDM4E | |
| SCHEMBL10265412 | 0.85 | PARP1 (0.51) | CPS1POLBTSHR | |
| SCHEMBL25085646 | 0.83 | L3MBTL3 (0.52) | CPS1MTOR | |
| SCHEMBL7903535 | 0.81 | POLB (0.55) | POLBHPGDRAB9ANPC1KMT2A | |
| SCHEMBL3901062 | 0.81 | POLB (0.55) | POLBHPGDRAB9ANPC1KMT2A | |
| SCHEMBL7878686 | 0.80 | CPS1 (0.60) | CPS1HPGDUSP2RAB9ANPC1 | |
| SCHEMBL3901059 | 0.79 | POLB (0.54) | POLBHPGDUSP2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | CPS1 3575/4885POLB 1091/4885HPGD 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.